TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07684560: A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Oral Doses of Alpha-0261 Tablets in Patients With Chronic Spontaneous Urticaria, and the Effect of Fo

Sponsor: AlphaMol Science Ltd. (Shanghai) · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 48 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07684560 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07684560 Rescue Dossier →